Please assess the completion status of the following clinical trial:

Trial Title: CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~DISEASE CHARACTERISTICS:~* Histologically confirmed primary systemic (AL) amyloidosis~  * Tissue amyloid deposits or positive fat aspirate~* Meets 1 of the following criteria for AL type disease:~  * Serum or urine monoclonal protein by immunofixation electrophoresis~ * Plasmacytosis of bone marrow by monoclonal staining for kappa- or lambda-light chain isotype~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* SWOG 0-2~Life expectancy~* Not specified~Hematopoietic~* White blood count\> 3,000/mm\^3~* Hemoglobin \> 8 g/dL~* Platelet count \> 100,000/mm\^3~* Absolute neutrophil count \> 1,000/mm\^3~Hepatic~* Bilirubin ≤ 2 times upper limit of normal (ULN)~* aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2 times ULN~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Prior thalidomide for AL amyloidosis allowed~Chemotherapy~* More than 4 weeks since prior cytotoxic chemotherapy~Endocrine therapy~* Prior steroids for AL amyloidosis allowed~Radiotherapy~* More than 4 weeks since prior radiotherapy~Surgery~* Prior surgery allowed~Other~* Recovered from all prior therapy~Exclusion Criteria:~* No secondary or familial amyloidosis~* No multiple myeloma, defined as ≥ 30% plasma cells in bone marrow biopsy specimen OR lytic bone lesions~* No prior CC-5013~Renal~* No dialysis~Cardiovascular~* No symptomatic cardiac arrhythmia~* No oxygen-dependent restrictive cardiomyopathy~Other~* No untreated or uncontrolled infection~* No other malignancy except basal cell skin cancer or carcinoma in situ of the cervix or breast~* No other serious medical illness that would preclude study participation~* No history of hypersensitivity reaction to thalidomide~* HIV negative~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- revlimid (Type: EXPERIMENTAL): lenalidomide 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone 20 mg daily (10 mg BID) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).